Home > Insider Trading > Filing (0001171843-14-005849)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
3116	Akorn Inc	AKRX	Pharmaceutical Preparations (2834)	720717400

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1324254	R John Sabat	1925 West Field Court Suite 300 Lake Forest IL 60045	Sr. V.p. National Accts Sales	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-12-08	25,000	$1.46	65,256	No	4	M	Direct
Common Stock	Disposition	2014-12-08	25,000	$40.04	40,256	No	4	S	Direct
Common Stock	Acquisiton	2014-12-09	18,173	$2.61	58,429	No	4	M	Direct
Common Stock	Disposition	2014-12-09	18,173	$41.21	40,256	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2014-12-08	25,000	$0.00	25,000	$1.46
Common Stock	Stock Options (Right to Buy)	Disposition	2014-12-09	18,173	$0.00	18,173	$2.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2020-02-22	No	4	M	Direct
0		2015-05-21	No	4	M	Direct

Footnotes

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $40.00 to $40.15 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at separate prices within the foregoing range.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $41.20 to $41.31 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at separate prices within the foregoing range.
Amount of Shares Beneficially Owned Following Reported Transaction includes 2,882 unvested shares subject to restricted stock awards and 37,374 shares owned outright.
The option vested in three annual installments with 25,000 options vesting on each of February 22, 2011, February 22, 2012, and February 22, 2013.
There was no consideration given in exchange for the security.
The option vested in three annual installments with 13,333 options vesting on each of May 21, 2011 and May 21, 2012, and 13,334 options vesting on May 21, 2013.